Compare YSG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | TBPH |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 993.7M |
| IPO Year | 2020 | N/A |
| Metric | YSG | TBPH |
|---|---|---|
| Price | $4.09 | $18.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | 238.0K | ★ 502.9K |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $571,300,568.00 | $80,327,000.00 |
| Revenue This Year | $28.96 | $70.78 |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | ★ N/A | $31.54 |
| Revenue Growth | 22.59 | ★ 27.12 |
| 52 Week Low | $3.01 | $7.90 |
| 52 Week High | $11.57 | $20.33 |
| Indicator | YSG | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 57.13 |
| Support Level | $3.88 | $17.59 |
| Resistance Level | $4.45 | $19.22 |
| Average True Range (ATR) | 0.22 | 0.62 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 33.08 | 81.50 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).